Greenwich LifeSciences Set to Present FLAMINGO-01 Data at AACR 2026 — Greenwich LifeSciences, Inc.

Event summary

Two abstracts from Greenwich LifeSciences accepted for AACR Annual Meeting 2026, including one co-authored with FLAMINGO-01 Steering Committee.
FLAMINGO-01 Phase III trial shows ~80% reduction in recurrence rate in non-HLA-A*02 arm after Primary Immunization Series (PIS).
Over 1,000 patients screened for FLAMINGO-01, with 250-patient non-HLA-A*02 arm fully enrolled.
AACR 2026 conference scheduled for April 17–22, 2026; abstracts and posters to be published in March/April.

The big picture

Greenwich LifeSciences' upcoming AACR presentation underscores the strategic importance of FLAMINGO-01 in validating GLSI-100 as a next-generation immunotherapy for breast cancer recurrence prevention. The trial's expanding patient enrollment and preliminary efficacy data signal potential market disruption in HER2-positive breast cancer treatment, where current options offer limited protection. Success here could position Greenwich LifeSciences as a key player in personalized oncology.

What we're watching

Trial Efficacy Validation: Whether preliminary ~80% recurrence reduction in non-HLA-A*02 arm sustains through full FLAMINGO-01 data analysis.
Regulatory Milestones: The pace at which GLSI-100 progresses toward potential FDA approval based on Phase III results.
Market Differentiation: How Greenwich LifeSciences positions GLSI-100 against existing therapies offering 20–50% recurrence reduction.